Becky Cap

Becky Butler Cap is a life science executive who has spent her career focused on the practical activities required to make visions become reality.  The first half of her career focused on contributing to the development of the oncology pharmaceutical market, supporting clinical trials at Dana-Farber, then market assessments and commercialization strategy for early targeted and immuno-oncology products, including Gleevec / Glivec, Rituxan, Keytruda, and a number of follow-on products and life cycle management plans in oncology and auto-immune diseases and other genetic conditions.

For the past decade, she has worked with blood banks to create spaces for them to support the development of cell-based or cell-derived biotherapies, especially in the cell and gene therapy industry.  Most of that work has focused on manufacturing, testing and apheresis support, both for autologous and allogeneic products.

Cap joined Vitalant in 2024 and oversees the creation and growth of innovative service lines to support the development of novel biotherapeutics for patient care. As senior vice president, she is responsible for Vitalant’s portfolio of services for biotherapy developers, including product sourcing, processing and manufacturing, testing, storage and management. A frequent event speaker and panelist, Cap is a thought-leader on expanding access and improving clinical quality for cell and gene therapies.  She serves on the Board of Act for Hope and the THOR Network Foundation.  Cap holds a bachelor’s degree from Harvard University and Master of Business Administration from Boston University Graduate School of Management.